Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naive cohort study.

ABSTRACT: AIMS:To compare HbA1c and hypoglycaemia in insulin-naïve patients with type 2 diabetes (T2D) who initiated insulin glargine 300?units/mL (Gla-300) or 100?units/mL (Gla-100). MATERIALS AND METHODS:This retrospective cohort study examined electronic medical records of insulin-naïve adults with T2D who initiated Gla-300 or Gla-100 during March 2015 through to December 2016 with active records for ?12?months before and??6 months after initiation, and??1 valid HbA1c value during 6-month baseline and 90-180-day follow-up. Outcomes included HbA1c and hypoglycaemia. Cohorts were propensity score-matched (1:2) on baseline demographic and clinical characteristics. Sensitivity analyses were conducted using broader inclusion criteria. RESULTS:The matched cohorts included 1004 Gla-300 and 2008 Gla-100 initiators (mean age 60.4 years; 53.2% male). During 6-month follow-up, Gla-300 versus Gla-100 initiators had a greater mean HbA1c decrease (-1.52?±?2.08% vs. -1.30?±?2.12%; P?=?0.003) and more patients achieved HbA1c <7% (25.0% vs. 21.5%; P?=?0.029) and?<8% (55.0% vs. 49.2%; P?=?0.002); and HbA1c <7% (21.9% vs. 17.4%; P?=?0.003) and?<8% (49.1% vs. 41.8%; P?

SUBMITTER: Bailey TS 

PROVIDER: S-EPMC6618106 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature